CROSS-STANDARD public interest · Home/clinical medical device

China-to-Australia Medical Device Compliance Gap Matrix

AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical general electromedical device documentation against Australian TGA / ARTG requirements: ARTG inclusion and TGA classification, ISO 13485 QMS via TGA-recognised CAB, AS/NZS IEC 60601-1 and IEC 62304 electrical and software safety, Essential Principles clinical evidence, mandatory Australian Sponsor, and English labelling and UDI obligations.

Dataset 2026-06-11 Last verified 2026-06-12 6 rows

GAP MATRIX

Compliance Gap Matrix

Gap matrix
Compliance item Common China baseline Australia (TGA / ARTG) Gap / action Source + verification date
Clinical Evidence and Essential Principles Compliance — — The core concept of clinical evaluation is common to both NMPA and TGA, and existing Chinese clinical dossiers may provide a useful foundation. Key gaps: (1) TGA's Essential Principles framework must be directly addressed with a compliance checklist — a document format specific to Australian regulation with no direct NMPA equivalent form. (2) Clinical literature must generally be in English or accompanied by certified translation; Chinese-language literature used for NMPA purposes needs to be translated and re-assessed for TGA. (3) TGA may require clinical evidence from studies conducted on internationally recognised patient populations; Chinese clinical trial data may be accepted but TGA will consider population applicability. (4) For Class IIb/III/AIMD devices, TGA's expectation for clinical evidence depth is substantial and may require supplementary investigations beyond what NMPA accepted. (5) Post-market clinical follow-up (PMCF) plans and adverse event reporting systems must be established to TGA's requirements. Therapeutic Goods Administration (TGA), Australian Government Department of Health and Aged Care2026-06-12 · unverified
Labelling, UDI, and English Language Requirements — — Key labelling gaps for Chinese manufacturers entering Australia: (1) English-language labelling is mandatory — Chinese-only labels are not acceptable. All device labelling including instructions for use must be translated to English and comply with Australian format requirements. (2) The Australian Sponsor name and address, and the ARTG entry number, must appear on the label — these are Australia-specific elements requiring new label designs or compliant label overlays. (3) While both China and Australia use IMDRF-aligned UDI systems (GS1/HIBCC), the NMPA UDI database registration does not substitute for TGA UDI database registration. Manufacturers must register their UDI with the TGA database separately. (4) UDI phase-in timelines differ between NMPA and TGA — manufacturers must check the current TGA mandatory UDI dates for their specific device class. (5) Label artwork and any device-specific symbols must comply with ISO 15223 and Australian Therapeutic Goods Order requirements. Therapeutic Goods Administration (TGA), Australian Government Department of Health and Aged Care2026-06-12 · unverified
Market Authorisation — ARTG Inclusion / TGA Device Classification — — Key gaps for a Chinese manufacturer entering Australia: (1) An Australian Sponsor must be appointed — a legal entity in Australia — before any ARTG application can proceed. This is a mandatory structural requirement with no NMPA equivalent. (2) ARTG classification must be independently determined under TGA rules; NMPA class does not automatically convert. (3) For Class IIa and above, third-party conformity assessment body (CAB) audit evidence is required; the accepted audit standards pathway differs from NMPA. (4) The ARTG inclusion application is lodged and managed by the Australian Sponsor, not the overseas manufacturer directly. (5) Post-market obligations (adverse event reporting, recalls) fall primarily on the Australian Sponsor. Therapeutic Goods Administration (TGA), Australian Government Department of Health and Aged Care2026-06-12 · unverified
Quality Management System — ISO 13485 (TGA / CAB Audit) — — The QMS standard (ISO 13485) is the same international standard used in both China and Australia, so manufacturers already certified to ISO 13485 for NMPA purposes have a strong foundation. However, the key gap is the issuing body: the TGA requires the certificate to come from a TGA-recognised CAB. A certificate from a China-domestic NMPA-recognised body is not automatically accepted by TGA. Manufacturers typically need to obtain a fresh ISO 13485 audit from a body recognised by TGA (e.g., a body accredited under MDSAP, or an IMDRF-aligned certification body). The scope of certification must also match the specific device type being registered in Australia. Therapeutic Goods Administration (TGA), Australian Government Department of Health and Aged Care2026-06-12 · unverified
Electromedical Safety — AS/NZS IEC 60601-1 and IEC 62304 Software Safety — — The underlying IEC 60601-1 and IEC 62304 standards are internationally harmonised and the gap between GB 9706.1-2020 and AS/NZS IEC 60601-1:2015 is relatively narrow at the base standard level, since both derive from the same IEC source. However, key practical gaps remain: (1) AS/NZS IEC 60601-1 may incorporate Australian/New Zealand-specific amendments or annexes not present in the GB version — manufacturers must verify the specific AS/NZS edition requirements. (2) Test reports must be from accredited test laboratories (typically NATA-accredited or ILAC MRA member labs); Chinese domestic lab reports may not be accepted without accreditation recognised in Australia. (3) The AMDs incorporated into GB 9706.1-2020 (AMD2:2020) extend beyond the AS/NZS 2015 edition base — this can be an advantage for technical content but the specific AS/NZS version must still be formally met. (4) Software documentation to IEC 62304 / YY/T 0664 largely transfers, but must be presented in English and aligned to TGA technical documentation format. Therapeutic Goods Administration (TGA), Australian Government Department of Health and Aged Care2026-06-12 · unverified
Australian Sponsor Requirement — Mandatory Local Entity — — The Australian Sponsor requirement is a structural gap with no direct NMPA equivalent for a China-only manufacturer. A Chinese manufacturer wishing to supply devices in Australia must: (1) identify and appoint a qualified Australian Sponsor before any ARTG application can be made — this cannot be waived or substituted; (2) establish a formal Sponsor Agreement defining responsibilities and obligations; (3) understand that the Sponsor bears primary legal liability in Australia — if the Sponsor relationship is not properly structured, both manufacturer and Sponsor face regulatory risk. Finding and retaining a reputable Australian Sponsor is typically one of the first and most critical steps for any overseas manufacturer entering the Australian medical device market. Federal Register of Legislation, Australian Government (Therapeutic Goods Act 1989)2026-06-12 · unverified

E-E-A-T

Named editorial review

Pending named reviewer

Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.

Editorial controls

Rows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.

SOURCES

Official-source register.